Moffitt Cancer Center Signs Agreement with the International Personalized Cancer Center to Develop Personalized Cancer Care

April 10, 2014

WHO: Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, signs its first international business agreement with China’s International Personalized Cancer Center at the Tianjin Taishan Cancer Hospital.

WHAT: Moffitt will sign an agreement to contribute to a new collaborative effort with the newly envisioned International Personalized Cancer Center at the Tianjin Taishan Cancer Hospital. This is the first international alliance for Moffitt. The International Personalized Cancer Center, a new 1,000 bed hospital currently under construction in Tianjin, China, will have a strong focus on personalized cancer treatment and prevention, as well as a commitment to translating bench-to-bedside research to benefit patients in the United States and China.

Moffitt has been involved in a number of research projects jointly conducted in Tianjin and has trained graduate students, post-doctoral fellows, physician-scientists and research nurses from Tianjin since 2008.   

Moffitt President & CEO Dr. Alan F. List, M2Gen Founder & CEO Dr. William S. Dalton and Tampa City Councilman Mike Suarez will be on hand for the signing.

WHEN: Friday, April 11, at 4:30 p.m.

WHERE: Moffitt’s Vincent A. Stabile Research Building, 12902 Magnolia Drive, Tampa, Fla. 33612

About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the No. 1 cancer hospital in Florida and has been listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer since 1999. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion. For more information, visit, and follow the Moffitt momentum on Facebook, Twitter and YouTube.